AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10903487
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 microg twice daily
Trial: 16350719
Drug: Methylprednisolone i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone i.v. pulses followed by oral prednisone treatment (Group I)
Trial: 16350719
Drug: Anti-thyroid drugs
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thyroid drugs (Group II)
Trial: 7878754
Drug: CsA-ME (microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA-ME (microemulsion formulation)
Trial: 7878754
Drug: CsA-GC (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA-GC (corn oil-based soft gel cap)
Trial: 2228838
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g iv
Trial: 31502749
Drug: dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dapagliflozin 10 mg
Trial: 20333744
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional laser treatment
Trial: 17092377
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg)
Trial: 1944909
Drug: Felbamate (2,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbamate (2,300 mg/d)
Trial: 31583708
Drug: Smartphone-based exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based exposure treatment
Trial: 11943440
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment A
Trial: 20551460
Drug: Mesalazine 4
RxNorm normalized name: Mesalazine 400 mg gastro-resistant and prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 4 g/day
Trial: 7722711
Drug: Atole (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atole (high energy and high protein supplement: 163 kcals/682 kJ and 11.5 g protein per cup or 180 mL)
Trial: 7722711
Drug: Fresco (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresco (low energy, no protein supplement: 59 kcals/247 kJ in 180 mL)
Trial: 7722711
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement (immigrants, n = 144)
Trial: 1723468
Drug: Nitrendipine once
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine once daily
Trial: 1723468
Drug: Nitrendipine twice
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine twice daily
Trial: 11044759
Drug: Control (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (other pharmacological agents)
Trial: 8513519
Drug: Intramuscular Meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Meperidine (IM)
Trial: 2950914
Drug: Topical ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketoconazole shampoo
Trial: 28968858
Drug: 33% tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% tapering TNFi
Trial: 28968858
Drug: 66% tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 66% tapering TNFi
Trial: 26659791
Drug: sifalimumab (200-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sifalimumab (200-1200 mg) administered intravenously every 4 weeks for 52 weeks
Trial: 26659791
Drug: fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dosing of sifalimumab
Trial: 19571155
Drug: Cinnamon extract
RxNorm normalized name: Cinnamon Extract
DrugBank: Chinese cinnamon (DB16593)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon extract (Cinnulin PF) 250 mg, two times per day for 12 weeks
Trial: 15059043
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 40 mg once daily for 4 weeks
Trial: 15059043
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 40 mg once daily for 10 days
Trial: 15059043
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 40 mg once daily for 5 days
Trial: 15059043
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 40 mg (single-dose study)
Trial: 15059043
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole (first week) followed by oral esomeprazole
Trial: 7530677
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally twice a day until ANC was 1,000/microliters (Group I, n=29)
Trial: 7530677
Drug: G‐CSF from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF from Day 2 until ANC was greater than 10,000/microliters (Group II, n=15)
Trial: 7530677
Drug: Ciprofloxacin with
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin with G‐CSF prophylaxis (n=24)
Trial: 3652622
Drug: Intravenous frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous frusemide (30 mg)
Trial: 25197804
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (100 mg)
Trial: 3652622
Drug: Oral carbidopa
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral carbidopa (100 mg)
Trial: 27279471
Drug: High-dose RO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose RO extract (HRE) 1800 mg/day
Trial: 27279471
Drug: Low-dose RO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose RO extract (LRE) 900 mg/day
Trial: 28828394
Drug: Teriflunomide 14
RxNorm normalized name: teriflunomide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide 14 mg
Trial: 22622860
Drug: Teriflunomide 7
RxNorm normalized name: teriflunomide 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide 7 mg
Trial: 23733165
Drug: Monopolar spray
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monopolar spray coagulation (Group A)
Trial: 20419973
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of verapamil every 14 days for 6 months
Trial: 16882525
Drug: Water treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water treatment (active)
Trial: 11076816
Drug: Continuous prostacyclin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous prostacyclin infusion
Trial: 3901764
Drug: Prepidil gel
RxNorm normalized name: dinoprostone Vaginal Gel [Prepidil]
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prepidil gel (0.5 mg)
Trial: 26423685
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after Axitinib
Trial: 15584064
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine 20 mg twice daily
Trial: 15584064
Drug: Topical 0.2
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2 percent glyceryl trinitrate ointment
Trial: 11903078
Drug: Epidural PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural PCA with bupivacaine 0.06% and sufentanil 1 microg x ml(‐1)
Trial: 11903078
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.15 mg
Trial: 9619712
Drug: Goserelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin plus mitomycin (14 mg/m2 i.v. every 6 weeks)
Trial: 2939217
Drug: Ketanserin monotherapy
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin monotherapy
Trial: 901134
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy intervention
Trial: 901134
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy intervention (second year participants)
Trial: 31658111
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality intervention in addition to Traditional Occupational Therapy
Trial: 31658111
Drug: Traditional Occupational
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Occupational Therapy
Trial: 19400831
Drug: 0.1% copper-zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% copper-zinc malonate-containing cream applied twice daily
Trial: 14750756
Drug: 0.3 mg/mL
RxNorm normalized name: menthol 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/mL of adjunctive mitomycin C for 3 minutes
Trial: 10693993
Drug: Amoxicillin/clavulanate (45/6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Trial: 10693993
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg on Day 1, then 5 mg/kg daily on Days 2 through 5)
Trial: 9114916
Drug: GR 32191
RxNorm normalized name: cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GR 32191 (20 mg and 40 mg, orally)
Trial: 3080882
Drug: Prazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (1 to 8 mg per day)
Trial: 3080882
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 to 240 mg per day)
Trial: 3351815
Drug: Danazol treatment
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol treatment (6-month course)
Trial: 30731474
Drug: Linaclotide (290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linaclotide (290 μg)
Trial: 3839796
Drug: Prostaglandin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin inhibitor (naproxen sodium)
Trial: 24461665
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (PN)
Trial: 24461665
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (PN)
Trial: 23592317
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1,000 mg) and Vitamin E (400 IU)
Trial: 22909282
Drug: P. ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. ginseng extract (1 g/day)
Trial: 22909282
Drug: P. ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. ginseng extract (2 g/day)
Trial: 12492745
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg
Trial: 19076084
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg of indapamide retard with or without addition of 2‐4 mg of perindopril
Trial: 9513587
Drug: Nebulized furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized furosemide (40 mg)
Trial: 6109234
Drug: Phloctaphenin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloctaphenin (200 mg)
Trial: 6109234
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (200 mg)
Trial: 29166321
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g low glycemic index modified starch supplement (UCAN)
Trial: 29166321
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g high glycemic index glucose‐based supplement (G)
Trial: 27421617
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy delivered by telephone (CBT-T)
Trial: 27421617
Drug: Telephone-delivered nondirective
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered nondirective supportive therapy (NST-T)
Trial: 25386945
Drug: Common Elements
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common Elements Treatment Approach (CETA) delivered by lay counselors
Trial: 16899484
Drug: PATHOZYME‐TB Complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PATHOZYME‐TB Complex Plus commercial ELISA kit measuring immunoglobulin G against 38‐kDa and 16‐kDa recombinant antigens
Trial: 9667276
Drug: Postoperative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative therapy
Trial: 29976173
Drug: Point-of-care Circulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care Circulating Cathodic Antigen (POC-CCA) test integrated with praziquantel (PZQ) treatment.
Trial: 29976173
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) treatment without testing.
Trial: 27700210
Drug: Boron-based gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron-based gel
Trial: 22788723
Drug: AR-NT (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-NT (no surface treatment)
Trial: 21492364
Drug: Rivoglitazone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone 0.5 mg daily
Trial: 21492364
Drug: Rivoglitazone 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone 1.0 mg daily
Trial: 21492364
Drug: Rivoglitazone 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone 1.5 mg daily
Trial: 24843782
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily
Trial: 21492364
Drug: Rivoglitazone 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone 1.0 mg and 1.5 mg
Trial: 15609596
Drug: Self-prepared ear-dropping
RxNorm normalized name: Sus scrofa ear preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-prepared ear-dropping made by combined Chinese and Western drugs
Trial: 11067720
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Paroxetine
Trial: 27595728
Drug: 20% benzocaine
RxNorm normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% benzocaine gel
Trial: 8638859
Drug: Belief manipulation
RxNorm normalized name: Ora Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belief manipulation (active agent vs placebo)
Trial: 2513966
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam elixir (0.3 mg/kg)
Trial: 2513966
Drug: Intramuscular papaveretum
RxNorm normalized name: papaveretum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular papaveretum with hyoscine (0.3 mg/kg with 0.006 mg/kg)
Trial: 166586
Drug: Cytarabine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine (50 mg/m² body surface area, subcutaneously, once daily for 4 days)
Trial: 24633388
Drug: Antiplatelet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet and antithrombotic therapy (AP/AT)
Trial: 24633388
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet and antithrombotic therapy (AP/AT)
Trial: 26554619
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hyoscine‐N‐butylbromide
Trial: 12556949
Drug: Actimel (fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actimel (fermented milk preparation)
Trial: 12556949
Drug: Indian Dahi
RxNorm normalized name: Indian frankincense
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indian Dahi (fermented milk preparation)
Trial: 12556949
Drug: Ultra-heat-treated yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-heat-treated yoghurt preparation (control group)
Trial: 8733313
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (1000 kcal/day, casein based enteral nutritional formula)
Trial: 8733313
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (using pressure threshold load valve at 30% of Maximal Inspiratory Mouth Pressure) with nutritional supplement
Trial: 8733313
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (using pressure threshold load valve) without nutritional supplement
Trial: 8733313
Drug: No training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No training or nutritional supplement
Trial: 2665800
Drug: Betamethasone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (3 injections or more)
Trial: 2665800
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 injections or more)
Trial: 2665800
Drug: Betamethasone (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (before 34 weeks gestation, 3 injections or more)
Trial: 2665800
Drug: Placebo (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (before 34 weeks gestation, 3 injections or more)
Trial: 30664539
Drug: Combined Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Cognitive Processing Therapy (CPT) and smoking cessation treatment
Trial: 30664539
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment without CPT
Trial: 25140039
Drug: Afatinib (A)
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib (A) 40 mg/day
Trial: 25140039
Drug: Temozolomide (T)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (T) 75 mg/m2 for 21 of 28 days
Trial: 24024757
Drug: Sodium alginate
RxNorm normalized name: Sodium Alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium alginate suspension 20 mL three times a day
Trial: 7926494
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily
Trial: 15328899
Drug: Olanzapine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 mg titrated to 5 mg)
Trial: 11086300
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 lakh units of Vitamin A orally (experimental group)
Trial: 1533259
Drug: Chlorthalidone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (50 mg/day)
Trial: 3296295
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (breathing exercises emphasizing inspiration with forced expiration technique in gravity assisted positions)
Trial: 3296295
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (breathing exercises with positive expiratory pressure alternating with forced expiration technique in gravity assisted positions)
Trial: 3296295
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (breathing exercises with positive expiratory pressure and forced expiration technique in sitting position)
Trial: 30311825
Drug: α-Lipoic Acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-Lipoic Acid (7 mg/kg), Carnosine (6 mg/kg), Thiamine (1 mg/kg)
Trial: 25123219
Drug: 7-day-week therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day-week therapy
Trial: 18298358
Drug: Circuit class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circuit class therapy
Trial: 15516351
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% plus 0.150 mg of clonidine
Trial: 15516351
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)
Trial: 15516351
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% plus 0.150 mg of clonidine
Trial: 15516351
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)